Spots Global Cancer Trial Database for capmatinib
Every month we try and update this database with for capmatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | NCT03693339 | Cancer Lung Cancer Met... MET Gene Mutati... | Capmatinib | 18 Years - | Asan Medical Center | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib | NCT05675683 | Metastatic Non-... | Capmatinib | 18 Years - | Novartis | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | NCT03693339 | Cancer Lung Cancer Met... MET Gene Mutati... | Capmatinib | 18 Years - | Asan Medical Center | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation | NCT03693339 | Cancer Lung Cancer Met... MET Gene Mutati... | Capmatinib | 18 Years - | Asan Medical Center | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations | NCT06054191 | NSCLC BRAF V600 Mutat... MET Exon 14 Mut... | Dabrafenib + Tr... Capmatinib | 18 Years - | Sun Yat-sen University | |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | NCT05243641 | Metastatic Brea... Breast Cancer | Neratinib Capmatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | NCT04323436 | Carcinoma, Non-... | Spartalizumab Capmatinib spartalizumab p... | 18 Years - | Novartis | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | NCT05642572 | Recurrent Lung ... Stage IV Lung C... | Biospecimen Col... Capmatinib Computed Tomogr... Magnetic Resona... Osimertinib Ramucirumab | 18 Years - | SWOG Cancer Research Network | |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | NCT04460729 | Non-small Cell ... | Capmatinib | 18 Years - | Novartis | |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) | NCT05154344 | MET Alterations Non Small Cell ... METex14 Mutatio... | Capmatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | NCT03647488 | Carcinoma, Non-... | Capmatinib Spartalizumab Docetaxel | 18 Years - | Novartis | |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) | NCT05154344 | MET Alterations Non Small Cell ... METex14 Mutatio... | Capmatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | NCT04139317 | Non-small Cell ... | Capmatinib Pembrolizumab | 18 Years - | Novartis | |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | NCT02587650 | ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib | 18 Years - | University of California, San Francisco | |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma | NCT05135845 | Oesophageal Ade... Gastric Adenoca... | Capmatinib Spartalizumab | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | NCT04323436 | Carcinoma, Non-... | Spartalizumab Capmatinib spartalizumab p... | 18 Years - | Novartis | |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC | NCT04926831 | Non-small Cell ... | capmatinib | 18 Years - 90 Years | Novartis | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | NCT03040973 | Advanced Solid ... | Capmatinib Nazartinib Gefitinib Osimertinib | 18 Years - | Novartis | |
| Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | NCT05435846 | Metastatic Lung... Stage IV Lung C... | Capmatinib Trametinib | 18 Years - | University of California, San Francisco | |
| Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib | NCT05675683 | Metastatic Non-... | Capmatinib | 18 Years - | Novartis | |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | NCT04139317 | Non-small Cell ... | Capmatinib Pembrolizumab | 18 Years - | Novartis | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | NCT05642572 | Recurrent Lung ... Stage IV Lung C... | Biospecimen Col... Capmatinib Computed Tomogr... Magnetic Resona... Osimertinib Ramucirumab | 18 Years - | SWOG Cancer Research Network | |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | NCT04460729 | Non-small Cell ... | Capmatinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
